NCT00420459View on ClinicalTrials.gov

A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Fragile X Syndrome
Interventions
DRUG

Aripiprazole

All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.

Trial Locations (1)

46202

Riley Child and Adolescent Psychiatry Clinic - Riley Hospital for Children, Indianapolis

All Listed Sponsors
lead

Indiana University School of Medicine

OTHER

NCT00420459 - A Prospective Open-label Study of Aripiprazole in Fragile X Syndrome | Biotech Hunter | Biotech Hunter